Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
- 7 October 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic LymphomaJournal of Clinical Oncology, 2013
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside AnalogsJournal of Clinical Oncology, 2009
- Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2006
- Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patientsLeukemia, 2005
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory diseaseBlood, 2001
- Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucilBritish Journal of Haematology, 2000
- Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.Journal of Clinical Oncology, 1998
- Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.Journal of Clinical Oncology, 1993